Trade Gilead Sciences
Gilead Sciences, Inc., is an American biopharmaceutical company based in Foster City, California, focused on research and development of antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C and influenza, including Harvoni and Sovaldi. in June 1987, The Giliad Science Company was originally founded under the name Oligogen by Michael L. Riordan, a doctor. Riordan graduated from Washington University in St. Louis, Johns Hopkins School of Medicine and Harvard Business School. Three scientific consultants worked with Riordan to create the company: Peter Dervan of Caltech, Doug Milton of Harvard University, and Harold M. Weintraub of the Fred Hutchinson Cancer Research Center. Riordan has been CEO since the company was founded until 1996. Menlo Ventures, a venture capital firm where Riordan previously operated, made the first $2 million investment in Giliad. Riordan also recruited scientific advisers, including Nobel Laureate Harold Farmos, who later became director of the National Institutes of Health, and Jack Zustak, a 2009 Nobel Prize winner for physiology or medicine. Riordan recruited Donald Rumsfeld to join the board in 1988, followed by Pino S. Schmidt, Sr., Gordon Moore, and George B. Schultz. Riordan tried to hire Warren Buffett as an investor and board member, but it didn't work. The company focused its early research on making small strands of acid Nuclear (oligomers, or in particular, oligonucleotides) to target specific genetic code sequences - i.e. anti-allergic therapy, a form of gene therapy. Because of the expected healing potential of such research, Oligogen quickly changed its name to Giliad Science, after the reputed healing properties of the ancient balm of Giliad. By 1988, the company had moved its headquarters to the Vittenpark neighborhood of Foster City, where it had been based ever since. The company began developing small antiviral molecule treatments in 1991, when the company obtained the license of a range of nucleotidecompounds including tenofovir.